Does Tamiflu Cause Dizziness?
Yes, dizziness is a recognized adverse effect of Tamiflu (oseltamivir), though it occurs infrequently and at rates similar to placebo in clinical trials.
Evidence from FDA Drug Label and Clinical Trials
According to the FDA-approved drug label, dizziness occurred in 2% of adults taking oseltamivir 75 mg twice daily for treatment, compared to 3% in the placebo group 1. In prophylaxis studies, dizziness was reported in 1% of both oseltamivir and placebo recipients 1.
Multiple ACIP guidelines consistently report that dizziness was among the most common adverse events in clinical trials, but occurred in less than 5% of persons across all treatment studies combined 2, 3, 4, 2, 5, 6, 7, 6. Importantly, the frequency of dizziness was similar between those receiving oseltamivir and those receiving placebo 2.
Clinical Context and Interpretation
The key finding is that dizziness occurs at comparable rates in both oseltamivir-treated patients and placebo recipients, suggesting that dizziness may be more attributable to influenza illness itself rather than the medication 2, 3, 4. This is an important distinction when counseling patients.
Research evidence supports this clinical trial data. One study in dialysis patients receiving prophylactic oseltamivir found dizziness in 9.1% of participants, though this was in a special population with end-stage renal disease 8.
Most Common Adverse Effects
The predominant adverse effects of oseltamivir are gastrointestinal: nausea (approximately 10%) and vomiting (approximately 9%) in adults, which are significantly more frequent than with placebo 2, 1. These GI symptoms:
- Are generally mild to moderate in severity
- Usually occur in the first 2 days of treatment
- May be reduced by taking oseltamivir with food 2
- Lead to discontinuation in less than 1% of patients 2
Important Safety Considerations
While dizziness is mild and uncommon, clinicians should be aware of more serious neuropsychiatric events:
Transient neuropsychiatric events (delirium, self-injury, abnormal behavior) have been reported postmarketing, primarily in Japanese adolescents and adults 2, 6. However, multiple analyses found oseltamivir is not associated with increased risk for these events 2. The FDA advises close monitoring for abnormal behavior 2, 6.
Recent case reports document oseltamivir-induced delirium in older adults with end-stage renal disease receiving prophylactic dosing 9, suggesting particular vigilance is warranted in elderly patients with renal impairment or dementia.
Clinical Recommendation
Dizziness should not be considered a contraindication to oseltamivir use or a reason to discontinue therapy, as it occurs at similar rates to placebo and is likely related to influenza illness itself. When patients report dizziness on oseltamivir, reassure them this is typically mild, self-limited, and not necessarily drug-related. Focus counseling instead on the more common GI side effects and the recommendation to take the medication with food to improve tolerability.